

SUPPLEMENTARY MATERIALS

A Series of Novel Integrastatins Analogues: In Silico Study of Physicochemical and Bioactivity Parameters

Aida S. Rakhimzhanova¹ , Ruslan A. Muzaparov¹ , Irina A. Pustolaikina^{1*} ,
Alfiya F. Kurmanova¹, Sergey N. Nikolskiy¹ , Darya D. Kapishnikova² ,
Alena L. Stalinskaya³ , Ivan V. Kulakov³ 

¹Department of Physical and Analytical Chemistry, Karaganda Buketov University, Karaganda, Kazakhstan;

²Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia;

³Higher School of Natural Science, University of Tyumen, Tyumen, Russia









(*Corresponding author's e-mail: ipustolaikina@gmail.com)









List of Content

2D molecular structures of the tested compounds and their IUPAC names (Table S1)	S2
3D optimized molecular structures of the tested compounds (Table S2)	S5
HOMO and LUMO frontier molecular orbitals diagrams (Table S3)	S7
Molecular electrostatic potential map (MEP) of 7a-u molecules (Table S4)	S13
Protein 3V81 - Ligand 7u interactions (Table S5)	S17
Protein 7AAP - Ligand 7u interactions (Table S6)	S18
Protein 4GQS - Ligand 7r interactions (Table S7)	S19

T a b l e S 1

2D molecular structures of the tested compounds and their IUPAC names

Compound	IUPAC names
 2a	1-((5S,11S)-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2b	1-((5R,11R)-9-bromo-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2c	1-((5R,11R)-2,5-dimethyl-9-nitro-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2d	1-((5R,11R)-9-hydroxy-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2e	1-((5R,11R)-9-methoxy-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2f	(5R,11R)-3-acetyl-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridine-9-carbaldehyde
 2g	1-((5R,11R)-8-hydroxy-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2h	1-((5R,11R)-9-bromo-8-hydroxy-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one

Compound	IUPAC names
 2i	1-((5R,11R)-8-hydroxy-2,5-dimethyl-9-nitro-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2j	1-((5R,11R)-9-allyl-7-methoxy-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2k	1-((5R,11R)-7-bromo-9-methoxy-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2l	1-((5R,11R)-7,9-dibromo-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2m	(5R,11R)-3-acetyl-7-bromo-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridine-9-carbaldehyde
 2n	1-((5R,11R)-7-bromo-2,5-dimethyl-9-nitro-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2o	1-((5R,11R)-9-methoxy-2,5-dimethyl-7-nitro-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2p	(5R,11R)-3-acetyl-2,5-dimethyl-7-nitro-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridine-9-carbaldehyde






















Compound	IUPAC names
 2q	1-((5R,11R)-9-bromo-2,5-dimethyl-7-nitro-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2r	1-((5R,11R)-2,5-dimethyl-7,9-dinitro-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2s	1-((5R,11R)-7,9-dibromo-8-hydroxy-2,5-dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2t	1-((5R,11R)-7-bromo-8-hydroxy-2,5-dimethyl-9-nitro-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-b]pyridin-3-yl)ethan-1-one
 2u	1-((8R,14R)-8,11-dimethyl-13,14-dihydro-8H-8,14-epoxynaphtho[1',2':7,8]oxocino[4,3-b]pyridin-10-yl)ethan-1-one









Table S2

3D optimized molecular structures of the tested compounds

		
2a	2b	2c
		
2d	2e	2f
		
2g	2h	2i
		
2j	2k	2l
		
2m	2n	2o



















HOMO and LUMO frontier molecular orbitals diagrams



	2a	2b
HOMO		
E, A.U.	-0,24009	-0,23887
LUMO		
E, A.U.	-0,07858	-0,08015
	2c	2d
HOMO		
E, A.U.	-0,25979	-0,22295
LUMO		
E, A.U.	-0,11039	-0,07932

	2e	2f
HOMO		
E, A.U.	-0,22009	-0,25120
LUMO		
E, A.U.	-0,07857	-0,08090
	2g	2h
HOMO		
E, A.U.	-0,23257	-0,23383
LUMO		
E, A.U.	-0,07847	-0,07887


	2i	2j
HOMO		
E, A.U.	-0,25565	-0,22203
LUMO		
E, A.U.	-0,10513	-0,07846
	2k	2l
HOMO		
E, A.U.	-0,22575	-0,24301
LUMO		
E, A.U.	-0,07923	-0,08004


	2m	2n
HOMO		
E, A.U.	-0,25430	-0,26115
LUMO		
E, A.U.	-0,08350	-0,11425
	2o	2p
HOMO		
E, A.U.	-0,23710	-0,26497
LUMO		
E, A.U.	-0,10920	-0,11274


	2q	2r
HOMO		
E, A.U.	-0,25372	-0,26861
LUMO		
E, A.U.	-0,11311	-0,11923
	2s	2t
HOMO		
E, A.U.	-0,23929	-0,25988
LUMO		
E, A.U.	-0,07972	-0,10819


	2u	
H O M O		
E, A.U.	-0,22553	
L U M O		
E, A.U.	-0,07880	

Molecular electrostatic potential map (MEP) of 2a-u molecules











Protein 3V81 -Ligand 2u interactions


Receptor surface: Aromatic




Receptor surface: H-Bond




Receptor surface: Charge




Receptor surface: Hydrophobic



Receptor surface: Ionizability




Receptor surface: SAS




Protein 7AAP-Ligand 2u interactions


Receptor surface: Aromatic




Receptor surface: H-Bond




Receptor surface: Charge




Receptor surface: Hydrophobic



Receptor surface: Ionizability




Receptor surface: SAS




Protein 4GQS -Ligand 2r interactions

Receptor surface: Aromatic




Aromatic
Edge
Face

Receptor surface: H-Bond




H-Bonds
Donor
Acceptor

Receptor surface: Charge




Interpolated Charge
0,100
0,067
0,033
0,000
-0,033
-0,067
-0,100

Receptor surface: Hydrophobic




Hydrophobicity
3,00
2,00
1,00
0,00
-1,00
-2,00
-3,00

Receptor surface: Ionizability



Ionizability
Basic
Acidic

Receptor surface: SAS



SAS
25,0
22,5
20,0
17,5
15,0
12,5
10,0